Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

The Board of Directors of The AES Corporation (NYSE: AES) declared a quarterly common stock dividend of $0.17595 per share ...

AES Corp is not a stock that makes headlines for significant price fluctuations, but investors were startled this week when it increased almost 20% in just one session.

AES Corp. closed 38.87% below its 52-week high of $20.30, which the company reached on October 1st.

AES Corporation’s core value still hinges on major data center power contracts and steady cash flows. Click here to find out ...

According to a report by Bloomberg, The AES Corporation (NYSE:AES) is mulling over selling the company after receiving ...

AES shares are trading higher after Bloomberg reported that the company is exploring options amid takeover interest.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares in AES Corp. are jumping in early trading Wednesday as the renewable energy firm reportedly explores selling itself, among other options, as it faces takeover interest.

Continuing questions about the impact of Trump administration tariffs caused U.S. equities to be higher but little changed at ...

For one thing, AES is viewed as a play on rising demand for electricity to power artificial intelligence data centers. For ...

Utility stock AES Corp (NYSE:AES) is surging today, up 16% at $12.84 at last glance, after reports that the company is ...